Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$816.65 USD
-12.78 (-1.54%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $816.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$816.65 USD
-12.78 (-1.54%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $816.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).
Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall
by Zacks Equity Research
Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQEW
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
by Zacks Equity Research
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
by Zacks Equity Research
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Alimera (ALIM) Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
by Zacks Equity Research
AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.
Top Research Reports for AbbVie, Intel & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
by Zacks Equity Research
Alimera's (ALIM) stock jumps 19.4% after the company inks a deal with Eyepoint to acquire additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
by Zacks Equity Research
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?